Viking Therapeutics VKTX reported a third-quarter 2025 loss of 81 cents per share, wider than the Zacks Consensus Estimate of a loss of 70 cents. The company had incurred a loss of 22 cents per share ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback